Ypsomed has been the exclusive distributor of Insulet‘s (NSDQ:PODD) Omnipod insulin management system in Europe since 2010. But today, the companies announced that the arrangement is slated to end on June 30, 2018, after the pair could not agree on extending the contract based on the price set by Insulet, according to Ypsomed.
Insulet said it will assume the distribution, sales and marketing activities for Omnipod across Europe after the contract expires in 2018. At that time, Ypsomed plans to develop a tubeless insulin pump system, the mylife YpsoPump, using the insulin pump that is already a part of its portfolio.
Get the full story at our sister site, Drug Delivery Business News.
The post Insulet, Ypsomed go their separate ways appeared first on MassDevice.